Optimizing a Unique Cancer Vaccine for Intradermal Delivery

Author(s)Muctarr Sesay, Mark Tomai, Steven Fuller

Using a hollow microstructured transdermal system to deliver vaccine directly to the dermis.

3M Drug Delivery Systems and Panacea Pharmaceuticals are collaborating to deliver Panacea’s investigational cancer vaccine, PAN- 301-1, directly to the dermis via the 3M hollow microstructured transdermal system (hMTS).

PAN-301-1 vaccine is a biologic that cannot be administered orally, or via a transdermal patch; therefore, it was thought that intradermal delivery to the skin could potentially be the optimal route of administration. The hMTS offers high-volume, reproducible, direct delivery capability to the highly-vascularized dermis.

Download the

BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook

.

Article Details

BioPharm International eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 31-35

Citation

When referring to this article, please cite it as S. Fuller et al., "Optimizing a Unique Cancer Vaccine for Intradermal Delivery, " BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).

Articles in this issue

about 8 years ago

Article

Patenting Prospects for Cell-Based Therapies

about 8 years ago

Article

Harvest of Human Mesenchymal Stem Cells from Microcarriers

about 8 years ago

Article

Affinity Chromatography Accelerates Viral Vector Purification for Gene Therapies

about 8 years ago

Article

End-to-End Cell Therapy Automation: An Immunotherapy Case Study

about 8 years ago

Article

Accelerating Genetic Medicine R&D Using Microfluidics

about 8 years ago

Article

Overcoming Hurdles in Emerging Therapy Development

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!